Development of an amorphous based sustained release system for apremilast a selective phosphodiesterase 4 (PDE4) inhibitor
first_published_at:March 5, 2022, midnight / date_published:March 5, 2022
Papers
-
05/03/2022 -
by
Qiangnan Zhang,
Thomas Durig,
Benjamin Blass,
Reza Fassihi
Apremilast, a selective PDE4 inhibitor approved for various inflammatory disorders, is categorized as a BCS-IV drug and exists in seven polymorphic forms. This study outlines the creation of a sustained-release …
